About Verastem

Management Team

Robert Forrester, LL.B., President/Chief Executive Officer

Mr. Forrester has 14 years of experience as the CEO, COO or CFO of both private and public life science companies with Forma Therapeutics, CombinatoRx (NASDAQ: CRXX, now ZLCS) and Coley (NASDAQ: COLY, acquired by Pfizer). Robert was a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks, BZW (now Barclays Capital) and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Robert started his career as lawyer with Clifford Chance in London and Singapore. Robert has completed over $12 billion of transactions and holds a LL.B. from Bristol University.

Top of Page

Christoph Westphal, M.D., Ph.D., Executive Chairman

Dr. Westphal is a Founder and Partner of Longwood Fund, which founds and invests in medical companies. Dr. Westphal currently serves as the co-founder, CEO and Chairman of Longwood portfolio company Flex Pharma (NASDAQ: FLKS) and co-founder, former CEO, and Executive Chairman of Longwood portfolio company Verastem (NASDAQ: VSTM). Dr. Westphal also co-founded Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010) and OvaScience (NASDAQ: OVAS). In addition, he co-founded Sirtris in 2004 (NASDAQ: SIRT; acquired by GSK), and served as CEO until 2010. Dr. Westphal previously served as co-founder/CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY), Acceleron Pharmaceuticals (NASDAQ: XLRN) and Momenta Pharmaceuticals (NASDAQ: MNTA). Companies founded by Dr. Westphal have invented important drugs, including the largest-selling heparin in the US, and several experimental medicines: for cystic fibrosis (phase 3), for currently incurable cancers (phase 2), and for serious inflammatory disorders (phase 2). In addition, these companies have created substantial shareholder value and aggregate market capitalizations (sustained) of over $12 billion. Dr. Westphal was appointed to the BIO Emerging Companies Section Governing Board and serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra. He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in leading journals such as Cell, Nature and Nature Genetics. Dr. Westphal has been featured in the media, including on ‘60 Minutes’, CNN, an ABC News Special hosted by Barbara Walters, and as the subject of a Fortune cover article.

Top of Page

Joanna Horobin, M.B., Ch.B., Chief Medical Officer

Dr. Horobin has 30 years of pharmaceutical drug development experience and has overseen the development or commercial launch of 10 novel drugs. As President of Syndax Pharmaceuticals Dr. Horobin designed and implemented the phase 2 clinical development of Entinostat in metastatic breast and lung cancer. Entinostat has been awarded “Breakthrough” designation by the FDA. Formerly VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY), COO of CombinatoRx (NASDAQ: CRXX, now ZLCS) and EVP at EntreMed with experience spanning clinical development, marketing, and general management in both public and private companies. Dr. Horobin was VP, Oncology at Rhone-Poulenc Rorer (now Sanofi, NYSE: SNY) where she led the global oncology business, including the successful global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim). Previously, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®. Dr. Horobin received her medical degree from the University of Manchester, England. While in clinical practice she gained membership to the Royal College of General Practitioners in the United Kingdom and holds a diploma of pharmaceutical medicine from the Royal College of Physicians in the United Kingdom.

Top of Page

Jack Green Chief Financial Officer

Mr. Green was a key member of the senior management team for On-Q-ity and oversaw the financial activities, planning, budgeting and management of commercial and banking relationships. Previously, Mr. Green was the Senior Vice President and Chief Financial Officer of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), which was spun out from Genzyme Corporation as a stand-alone public company. Mr. Green is a Certified Public Accountant (CPA) with over 30 years of financial experience, including 20 within the biotechnology industry. Mr. Green received a Master’s degree in business administration from Boston University Graduate School of Management and a Bachelor’s degree from the College of the Holy Cross.

Top of Page

Jonathan Pachter, Ph.D., Head of Research

Dr. Pachter brings over 25 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor which progressed to phase III clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab which advanced to phase II clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 50 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.

Top of Page

Dan Paterson, Chief Operating Officer

Mr. Paterson has over 20 years of experience in management roles at healthcare and biotechnology companies, including as COO and CEO, and specific expertise in oncology drug and diagnostic product development. Mr. Paterson was the founding CEO of The DNA Repair Company (acquired by On-Q-ity) which develops oncology-focused molecular diagnostics. Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health after playing a key role in the acquisition of PharMetrics by IMS Health as VP, Marketing and Corporate Development. Mr. Paterson was on the founding management team of CareTools, a healthcare information systems company, OnCare, an oncology physician practice management company with $100 million in annual revenue, and Axion, a oncology pharmaceutical and clinical service firm with an annual revenue of over $250 million when acquired by Bristol Myers Squibb. Mr. Paterson has designed and managed clinical trials in both industry and academic settings and holds a B.A. in Biology from Boston University.

Top of Page